子宫内膜癌中microR-125b和高迁移率族蛋白A1的表达水平及临床意义

Expression levels and clinical significance of MiR-125b and HMGA1 in endometrial carcinoma

目的探究microRNA-125b(miR-125b)、高迁移率族蛋白A1(HMGA1)在子宫内膜癌中的表达水平及临床意义,为寻找子宫内膜癌诊治及预后的靶基因奠定理论基础。方法收集西安市第九医院于2010年1月-2012年12月手术切除并经病理检查确诊的85例子宫内膜癌组织标本,同时取30例相应癌旁组织和30例正常子宫组织作为对照。实时定量PCR(qRT-PCR)技术检测子宫内膜癌组织miR-125b水平;蛋白质印迹(Western blot)技术检测子宫内膜癌组织HMGA1水平;结合临床资料分析miR-125b、HMGA1与子宫内膜癌临床病理特征及预后的关系。结果①miR-125b在子宫内膜癌组织中的表达水平显著低于正常组织和癌旁组织,差异有统计学意义(均P<0.05)。②HMGA1在子宫内膜癌组织中的表达水平显著高于正常组织和癌旁组织,差异有统计学意义(均P<0.05)。③子宫内膜癌组织miR-125b、HMGA1的表达与病理分期、子宫肌层浸润深度、淋巴结转移均有关,差异有统计学意义(均P<0.05)。④子宫内膜癌组织中miR-125b表达水平与HMGA1表达水平显著呈负相关(r=-0.518,P<0.05)。⑤miR-125b高表达组5年生存率为59.66%,明显高于miR-125b低表达组31.24%,差异有统计学意义(P<0.05);HMGA1低表达组5年生存率为67.12%,明显高于HMGA1高表达组31.11%,差异有统计学意义(P<0.05)。分期越晚的HR为4.707,95%CI为3.412~21.481;miR-125b低表达的HR为0.319,95%CI为0.150~0.932;HMGA1高表达的HR为0.478,95%CI为0.369~0.886。结论子宫内膜癌组织中miR-125b表达下调、HMGA1表达上调,且呈负相关,均可用来评估子宫内膜癌患者的临床预后。

Objective To explore the expression levels and clinical significance of MiR-125b and high mobility group protein A1 ( HMGA1) in endometrial carcinoma,lay a theoretical foundation for finding the target genes for diagnosis,treatment,and prognosis of endo- metrial carcinoma. Methods Eighty-five patients undergoing survery and diagnosed as endometrial carcinoma definitely by pathological ex- amination in the Nineth Hospital of Xi'an from January 2010 to December 2012,the endometrial carcinoma tissue specimens and 30 cases of corresponding para-carcinoma tissue specimens were obtained,30 cases of normal uterine tissue specimens were selected as control group. Real-time quantitative PCR ( qRT-PCR) was used to detect the level of miR-125b in endometrial carcinoma tissue;Western Blot was used to detect the level of HMGA1 in endometrial carcinoma tissue;the relationships between miR-125b,HMGA1 and clinicopathological fea- tures,prognosis of endometrial carcinoma were analyzed combined with clinical data. Results The expression level of miR-125b in endom- etrial carcinoma tissue was statistically significantly lower than those in normal tissue and para-carcinoma tissue ( P<0. 05). The expression level of HMGA1 in endometrial carcinoma tissue was statistically significantly higher than those in normal tissue and para-carcinoma tissue ( P<0. 05). The expression levels of miR-125b and HMGA1 in endometrial carcinoma tissue were correlated with pathological staging, depth of myometrium infiltration,and lymph node metastasis ( P<0. 05). The expression level of miR-125b in endometrial carcinoma tissue was negatively correlated with the expression level of HMGA1 ( r =-0. 518,P<0. 05). The five-year survival rate in miR-125b high ex- pression group was 59. 66%,which was statistically significantly higher than that in miR- 125b low expression group ( 31. 24%)( P < 0. 05). The five-year survival rate in HMGA1 low expression group was 67. 12%,which was statistically significantly higher than that in HMGA1 high expression group ( 31. 11%)( P<0. 05). HR of late stage was 4. 707 ( 95% CI: 3. 412-21. 481),HR of miR-125b ow ex- pression was 0. 319 ( 95% CI: 0. 150-0. 932),HR of HMGA1 high expression was 0. 478 ( 95% CI: 0. 369-0. 886). Conclusion The expression of miR-125b is down-regulated and the expression of HMGA1 is up-regulated in endometrial carcinoma tissue,showing a nega- tive correlation. miR-125b and HMGA1 can be used to evaluate the clinical prognosis of patients with endometrial carcinoma.